コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 showing that DJ34 is a DNA intercalator and topoisomerase II inhibitor.
2 (waf1) induction in response to etoposide, a topoisomerase II inhibitor.
3 vative, XWL-1-48, was synthesized as an oral topoisomerase II inhibitor.
4 calate into DNA double strands and is also a topoisomerase II inhibitor.
5 tion that they are induced by treatment with topoisomerase II inhibitors.
6 itumor effect of ionizing radiation (IR) and topoisomerase II inhibitors.
7 gents, including ionizing radiation (IR) and topoisomerase II inhibitors.
8 e specifically to mitoxantrone, not to other topoisomerase II inhibitors.
9 thesized dual-acting histone deacetylase and topoisomerase II inhibitors.
10 th DNA-damaging agents such as alkylators or topoisomerase II inhibitors.
11 -damaging agents, including radiotherapy and topoisomerase II inhibitors.
12 n tumor cell line intrinsically resistant to topoisomerase II inhibitors.
13 the MLL gene are associated with the use of topoisomerase II inhibitors.
14 cer treatment at low cumulative doses of DNA topoisomerase II inhibitors.
15 ication of primary cancer treatment with DNA topoisomerase II inhibitors.
16 eukemia who previously were treated with DNA topoisomerase II inhibitors.
17 ion of exposure to natural and synthetic DNA topoisomerase II inhibitors.
18 susceptible to breakage in cells exposed to topoisomerase II inhibitors.
19 ive to double-strand DNA cleavage induced by topoisomerase II inhibitors.
20 g chemotherapy with alkylating agents and/or topoisomerase II inhibitors.
21 with chemotherapeutic regimens incorporating topoisomerase II inhibitors.
22 Prior therapy in this patient included DNA topoisomerase II inhibitors, alkylating agents, and irra
23 ere treated with various combinations of DNA topoisomerase II inhibitors, alkylating agents, or irrad
24 Mice were treated with vehicle, M3814 alone, topoisomerase II inhibitor alone, and M3814 in combinati
28 , and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methot
29 e the mid-1980s, when the intensified use of topoisomerase-II inhibitors and alkylators first gained
30 hibitor alone, and M3814 in combination with topoisomerase II inhibitor, and change in tumor volume o
31 alkylating agent, the 27 who had received a topoisomerase II inhibitor, and the 37 who had received
33 hylamino N-oxide groups, is converted to the topoisomerase II inhibitor AQ4 [1,4-bis{[2-(dimethylamin
35 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive int
36 gp-170 P-glycoprotein, and one resistant to topoisomerase II inhibitors, CEM-VM1-5, which has a muta
37 zed with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used in SCLC chemot
38 role in effecting G(2) arrest in response to topoisomerase II inhibitors, depending upon the mechanis
39 ing that the bisdioxopiperazine class of DNA topoisomerase II inhibitors directly interacts with the
41 ession and enhanced chemosensitivity towards topoisomerase II inhibitor, doxorubicin, in breast cance
42 tivity of M3814 in combination with multiple topoisomerase II inhibitors, doxorubicin, etoposide, and
43 apy-related leukemias (t-ML) associated with topoisomerase II inhibitors (e.g., etoposide) and cause
44 has a cytotoxicity-protective effect against topoisomerase II inhibitor/E2F-1-induced apoptosis and s
45 be induced in mouse cells by exposure to the topoisomerase II inhibitor etoposide and is mediated in
46 our different epithelial cell lines with the topoisomerase II inhibitor etoposide in combination with
50 rt here that during apoptosis induced by the topoisomerase II inhibitor etoposide, a fraction of GRP9
51 ted apoptosis-inducing ligand (TRAIL) or the topoisomerase II inhibitor etoposide, which damages DNA.
56 ificantly enhances cell death induced by the topoisomerase II inhibitors etoposide and doxorubicin an
57 h this property, treatment of cells with the topoisomerase-II inhibitor etoposide promotes chromosoma
59 higher colony survival when challenged with topoisomerase II inhibitors, etoposide and doxorubicin,
60 and then exposed to Adriamycin (ADR), a DNA topoisomerase II inhibitor, exhibit an altered pattern o
62 ophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy.
63 ure to doxorubicin, a DNA-damaging agent and topoisomerase II inhibitor frequently used in cancer the
64 -OH ellipticine and cross-resistant to other topoisomerase II inhibitors has previously been shown to
65 emotherapy regimens for WT consist mainly of topoisomerase II inhibitors (i.e., actinomycin D, doxoru
66 ation could be prevented by treatment with a topoisomerase II inhibitor ICRF-193, suggesting that the
67 system to test whether aclacinomycin A is a topoisomerase II inhibitor in vivo and to test whether w
68 increased resistance to topoisomerase I and topoisomerase II inhibitors in a variety of human cell l
69 hibit NF-kappa B may enhance the efficacy of topoisomerase II inhibitors in clinical cancer chemother
71 e cellular ultrastructure that differed from topoisomerase II inhibitors including induction of spher
72 echanisms by which cleavable complex-forming topoisomerase II inhibitors interfere with DNA replicati
73 igh-dose use of alkylating agents given with topoisomerase-II inhibitors is strongly leukemogenic, ev
74 toposide, a widely used antitumor drug and a topoisomerase II inhibitor, is a prototypical inducer of
76 arrest induced by cleavable complex-forming topoisomerase II inhibitors leads to the generation of i
78 cific cleavage within the MLL bcr induced by topoisomerase II inhibitors may be an early step leading
79 e high-dose cyclophosphamide, cisplatin, and topoisomerase-II inhibitors may entail a considerable ri
80 706744) and NSC 724998, but sensitive to the topoisomerase II inhibitors mitoxantrone and etoposide.
81 These secondary leukemias associated with topoisomerase II inhibitors (most commonly teniposide, e
82 g kinase inhibitors, mitotic inhibitors, and topoisomerase II inhibitors, on both the cell growth rat
83 DNA lesions generated by etoposide, a DNA topoisomerase II inhibitor, or by exonuclease treatment
84 hesis and biological evaluation of novel DNA topoisomerase II inhibitors, podophenazine (8), 2'',3''
85 cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for m
87 reakage leading to MLL translocations in DNA topoisomerase II inhibitor-related leukemias is a conseq
88 a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in
89 ated stress protein (GRP78) are resistant to topoisomerase II inhibitors, such as etoposide, m-amsacr
90 e induced by chemotherapeutic agents such as topoisomerase-II inhibitors suggest that apoptogenic age
93 F-1-expressing cells with ICRF-193, a second topoisomerase II inhibitor that does not damage DNA, pro
95 We have previously reported on a family of topoisomerase II inhibitors that also interact with G-qu
96 s of the antibacterial fluoroquinolones, are topoisomerase II inhibitors that have demonstrated promi
97 Bisdioxopiperazines are a unique class of topoisomerase II inhibitors that lock topoisomerase II a
98 y twelve topoisomerase I inhibitors and four topoisomerase II inhibitors that unsilence the paternal
99 At the first detection of MLL-ENL, the only topoisomerase II inhibitors the patient had received wer
100 th topoisomerase I poison trials, ifosfamide/topoisomerase II inhibitor trials had superior FFS (P =
101 tions, including the quick construction of a topoisomerase II inhibitor via a Hiyama cross-coupling r
102 ases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing
103 genomic fusions can occur after exposure to topoisomerase II inhibitors, we developed a long-distanc
105 protect RCE and PRCE cells from etoposide, a topoisomerase II inhibitor, which induced cell death by
108 and 25 were "cleavable-complex"-forming DNA topoisomerase II inhibitors with either improved or simi